ライフサイエンスコーパス: plasma protein

1 sulted in expression of a hybrid CFHR2-CFHR5 plasma protein.

2 d-glycoprotein (AGP) as a chiral acute phase plasma protein.

3 y hemopexin (Hx), an endogenous heme-binding plasma protein.

4 on of selenium-sulfur bond between p-XSC and plasma protein.

5 to identification of a large number of novel plasma proteins.

6 active fragment production in the absence of plasma proteins.

7 d this might be involved in the retention of plasma proteins.

8 n and degradation along with accumulation of plasma proteins.

9 etition of bile acids with FL for binding to plasma proteins.

10 ng the abundance of 44 out of 45 major human plasma proteins.

11 n blood and are largely free from binding to plasma proteins.

12 strated capillaries, causing a major leak of plasma proteins.

13 premature aquation and binding to essential plasma proteins.

14 mplex mixture obtained by digestion of human plasma proteins.

15 cts with a select group of drusen-associated plasma proteins.

16 ssociated functionally with glycosylation of plasma proteins.

17 d thrombosis through its binding of adhesive plasma proteins.

18 acid-lysine-alanine, which binds to clotted plasma proteins.

19 condition of changing radioligand binding to plasma proteins.

20 ts identified a large number of differential plasma proteins.

21 become sensitive to neutralization by mouse plasma proteins.

22 s, however, increased expression of genes of plasma proteins.

23 ermitting routine quantification of multiple plasma proteins.

24 to cause enhanced glomerular permeability to plasma proteins.

25 However, bumetanide is heavily bound to plasma proteins (~98%) and highly ionized at physiologic

26 Pregnancy-associated plasma protein A (PAPPA) is a metalloproteinase that con

27 Trophoblast-derived pregnancy-associated plasma protein A (PAPPA) is specifically elevated in pre

28 Pregnancy-associated plasma protein-A (PAPP-A) is a large metalloproteinase s

29 to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment

30 ncin metalloproteinase, pregnancy-associated plasma protein-A (PAPP-A), which modulates insulin-like

31 ting metalloproteinase, pregnancy-associated plasma protein-A (PAPP-A).

32 ertebrate-specific gene pregnancy-associated plasma protein-aa (pappaa).

33 Combinations of plasma proteins accurately identified children with a re

34 distribution, charge, coating molecules, and plasma protein adsorption) that can be effectively tuned

35 o investigate how a systemic absence of this plasma protein affects leukocyte recruitment in alveolit

36 NP) to increase vascular permeability to the plasma protein albumin after an acute plasma volume expa

37 ides and tryptic peptides derived from human plasma proteins, allowing precursor ion selection and CI

38 h by mass spectrometry was identified as the plasma protein alpha1-microglobulin, an established mega

39 ly, we quantified urinary excretion of blood plasma proteins alpha1-microglobulin, albumin, and IgG.

40 We now show that this plasma protein also is highly susceptible to degradation

41 ecule (Evans blue dye) that is known to bind plasma proteins, an exogenous protein (tetanus toxin fra

42 SeP is a liver-derived plasma protein and a major supplier of selenium, which i

43 Plasma protein and brain tissue binding are very importa

44 ins are representatives of the main types of plasma protein and have different shapes and sizes.

45 Properdin is a plasma protein and is also released from neutrophil gran

46 Among 92 plasma proteins and 135 lipid subspecies quantified with

47 FeCl3 induces aggregation of all plasma proteins and blood cells, independent of endothel

48 1-2% (v/v) 1-butanol mobile phase to remove plasma proteins and concentrate the analytes at the colu

49 gulate the extravasation of small molecules, plasma proteins and inflammatory cells.

50 ng to oedema, excitotoxicity, and ingress of plasma proteins and inflammatory cells.

51 The liver is essential for the synthesis of plasma proteins and integration of lipid metabolism.

52 l tool for the unbiased in-depth analysis of plasma proteins and may advance biomarker discovery, as

53 After removing plasma proteins and microparticles, 1048 proteins were i

54 stitial space limits the space available for plasma proteins and other macromolecules.

55 Transport of plasma proteins and solutes across the endothelium invol

56 altered fucosylation of N-linked glycans on plasma proteins and that glycan biomarkers could improve

57 activated microglia/macrophages, astrocytes, plasma proteins, and blood vessels.

58 Compound 3 was 75% bound to human plasma proteins, and its metabolic stability was much gr

59 platelets with cellular adhesion molecules, plasma proteins, and lipids.

60 We used an aptamer-based assay of 1129 plasma proteins, and patient clinical details were conce

61 High-abundance plasma proteins are involved in disease-associated pathw

62 Since certain plasma proteins are regulated through extracellular phos

63 with many human diseases, only a handful of plasma proteins are routinely used in clinical tests.

64 we sought to identify coordinated changes in plasma proteins associated with breast cancer based on l

65 Our aim was to discover plasma proteins associated with early AD pathology by in

66 tibody prevents mural cell loss and modifies plasma proteins associated with Notch3 activity, includi

67 light mass spectrometry was used to identify plasma proteins associated with renal allograft rejectio

68 ibodies are shown to be directed against the plasma protein beta(2)-glycoprotein I and not against ph

69 oth values were significantly lower than the plasma protein binding (71% +/- 5%) and red cell uptake

70 ere significantly lower (P < 0.001) than the plasma protein binding (75% +/- 3%) and red cell uptake

71 of (99m)Tc-PSMA-I&S was observed due to high plasma protein binding (94%) of the tracer.

72 The plasma protein binding (PPB%) was calculated and found t

73 This peptide showed relative high plasma protein binding abilities and a human plasma half

74 n log D, solubility, in vitro clearance, and plasma protein binding also hold in transformation space

75 ng oligonucleotides (MTOs) provide increased plasma protein binding and biodistribution to liver, and

76 ctive starting point, (b) the probability of plasma protein binding and cytotoxicity are often increa

77 The plasma protein binding and erythrocyte uptake were deter

78 The plasma protein binding and red cell uptake of (99m)Tc(CO

79 The plasma protein binding and red cell uptake of (99m)Tc(CO

80 vations are presented to illustrate that low plasma protein binding does not necessarily lead to high

81 boxamide moiety at C-3 significantly reduced plasma protein binding effects in vitro.

82 o metabolic stability, plasma stability, and plasma protein binding for a representative set of compo

83 Plasma protein binding of (18)F-FDS was low (<0.1%), and

84 nges for drug development have been the high plasma protein binding of lead structures, interspecies

85 Plasma protein binding of Na(2)[(99m)Tc(CO)(3)(NTA)] ave

86 icantly changed the plasma concentration and plasma protein binding of radiotracer.

87 4, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of go

88 and hepatocyte stability, MDCK permeability, plasma protein binding).

89 ro studies show that 2d, 2h, and 2j have low plasma protein binding, a necessary condition for renal

90 ed high kidney extraction and excretion, low plasma protein binding, and high metabolic stability as

91 hat aqueous solubility, Caco-2 permeability, plasma protein binding, human ether-a-go-go-related pota

92 Plasma protein binding, red cell uptake, and percentage

93 Plasma protein binding, red cell uptake, and percentage

94 ompound 17 demonstrate low clearance and low plasma protein binding.

95 satisfactory liver microsomes stability and plasma protein binding.

96 monkeys, after correcting for differences in plasma protein binding.

97 alian cell lines was reduced, solubility and plasma-protein binding were improved while retaining pot

98 , low intrinsic microsome clearance, and low plasma-protein binding.

99 rafiltration assay was used to determine the plasma protein-binding properties of (177)Lu-cm09.

100 stments, and efforts, the ongoing search for plasma protein biomarkers for disease so far has come up

101 appointing state of affairs may suggest that plasma protein biomarkers have little more to offer for

102 rs, including hepatic transcription factors, plasma proteins, biotransformation enzymes, and metaboli

103 Serum and plasma proteins bound to the nanoworms are mostly interc

104 OT binds strongly to plasma proteins, but a reduction/alkylation (R/A) proced

105 ntify and quantify AGE modification sites in plasma proteins by reversed phase HPLC mass spectrometry

106 peripheral nervous system are shielded from plasma proteins by the blood-brain barrier and blood-ner

107 shock and is characterized by a decrease in plasma protein C (PC) levels.

108 performed a genome-wide association scan for plasma protein C antigen concentration with approximatel

109 n's substrate specificity toward cleavage of plasma protein C into activated protein C (APC), which o

110 ctivity, reduced EPCR shedding, and restored plasma protein C level.

111 The plasma protein C3 is a central element in the activation

112 ace were significantly associated with lower plasma protein carbonyl levels in unaffected sisters.

113 in humans was quantified by measuring blood plasma protein carbonyls using the two commercially avai

114 Plasma protein carbonyls were associated with an increas

115 lore factors that contribute to variation in plasma protein carbonyls, and to determine whether this

116 ients with organic acidemias showed elevated plasma protein carbonyls, while plasma samples from all

117 e, it engages a tightly regulated network of plasma proteins, cell surface receptors, and regulators.

118 ted with early AD pathology by investigating plasma protein changes at the asymptomatic and symptomat

119 uppress irreversible interactions with blood-plasma protein cocktails.

120 ogen and also vitronectin, and the two human plasma proteins compete for PE binding.

121 he major negative regulator of the AP is the plasma protein complement factor H (FH).

122 This study demonstrated that C3b:plasma protein complexes form in the fluid-phase during

123 The nonspecific binding of heparin to plasma proteins compromises its anticoagulant activity b

124 There was a significant reduction in total plasma protein concentration after plasmapheresis (p < .

125 We found that total plasma protein concentration increased during hibernatio

126 ontaneous breathing trial-induced changes in plasma protein concentration, 0.96 (0.90-1.01) for chang

127 Plasma protein concentration, hemoglobin concentration,

128 s has been shown to be more dependent on the plasma protein concentrations and the type of zeolites t

129 tor, assessed with the median cutoff method, plasma protein concentrations were also not associated w

130 Measurement of plasma protein concentrations with ELISA revealed a redu

131 ar lung water indexed for ideal body weight, plasma protein concentrations, hemoglobin concentration,

132 e natriuretic peptide level, hemoglobin, and plasma protein concentrations.

133 Histidine-rich glycoprotein (HRG) is a plasma protein consisting of 6 distinct functional domai

134 How the kidney prevents urinary excretion of plasma proteins continues to be debated.

135 ies showed that the complexes consisted of a plasma protein covalently bound to C3b in a 1:1 molar ra

136 We find internal cleavages in plasma proteins created by endo- and exopeptidases, prov

137 ght to be the transcellular pathway by which plasma proteins cross normal capillary endothelium, but,

138 ur mouse brain vasculome with representative plasma protein databases demonstrated significant overla

139 though the concentrations of most individual plasma proteins decreased, as did the white blood cell t

140 Among the 190 differential plasma proteins detected by iTRAQ, carbamoyl-phosphate s

141 wledge, this marks the lowest LOD for a real plasma protein detection based on label-free LSPR shift

142 tivity and ruggedness, compared to the whole plasma protein digestion approach alone.

143 Several different plasma proteins displayed a discrete high molecular SDS-

144 interactions contribute to the accretion of plasma proteins during drusen formation.

145 Kallistatin, an endogenous plasma protein, exhibits pleiotropic properties in inhib

146 M detection of seven out of eight endogenous plasma proteins expressed at ng/mL or subng/mL levels in

147 me or anticipate clinical trajectories using plasma protein expression would allow personalization of

148 ood-brain barrier breakdown characterized by plasma protein extravasation following fibrinogen and Ig

149 One of its most important regulators is the plasma protein factor H (FH).

150 ascade is triggered by the activation of the plasma protein factor XII (FXII) and leads to kallikrein

151 ficial surfaces and biologic substances, the plasma proteins factor XII (FXII) and prekallikrein unde

152 n of P. aeruginosa that binds the four human plasma proteins, Factor H, Factor H-like protein-1 (FHL-

153 s thrombin-catalyzed conversion of a soluble plasma protein, fibrinogen, into a polymeric fibrin clot

154 lin loss or paralysis onset and that, of the plasma proteins, fibrinogen specifically induces rapid a

155 erived hepatocytes produced and secreted the plasma proteins, fibrinogen, fibronectin, transthyretin,

156 or its interaction with collagen type IV and plasma proteins fibronectin and plasminogen.

157 ureus had sufficiently high solubility, high plasma protein free fraction, and favorable pharmacokine

158 gram increased the fraction unbound to human plasma protein from below minimum detection levels, i.e.

159 Plasma proteins from blood samples altered the ability o

160 paration and rapid measurement of a panel of plasma proteins from quantities of whole blood as small

161 We show that the plasma protein haptoglobin prevents the fatty acid-promo

162 Treatment with the naturally occurring human plasma proteins haptoglobin or hemopexin may have benefi

163 face area and high pore volume towards human plasma proteins has been investigated.

164 As plasma proteins have become a major thrust in the field

165 Recently, the liver-derived plasma protein, histidine-rich glycoprotein (HRG), was d

166 ycoprotein (HRG) is a 75-kDa heparin-binding plasma protein implicated in the regulation of tumor gro

167 of a comparison of the quantification of 100 plasma proteins in >1500 LC-MS runs, the SD range of the

168 We aimed to reveal the differential plasma proteins in 272 CHD patients with or without PAH.

169 We performed multianalyte profiling of 50 plasma proteins in 28 patients with persistent HCV infec

170 iologic hemostasis upon injury involves many plasma proteins in a well-regulated cascade of proteolyt

171 We analyzed a broad range of plasma proteins in children with well-characterized asth

172 h by serving as a comprehensive reference of plasma proteins in humans and accelerate biomarker disco

173 Two major plasma proteins in humans are primarily responsible for

174 ized that formation of a fibrin mesh retains plasma proteins in NPs.

175 Plasma proteins in patients who responded to standard tr

176 It bound strongly to plasma proteins in rats (97%), and its labeled metabolit

177 Here, turnover rates of plasma proteins in rats were measured in vivo using a pu

178 ndergo changes in morphology and internalize plasma proteins in response to this disorder.

179 re the roles of clumping factor A (ClfA) and plasma proteins in supporting adhesion.

180 The major plasma proteins in the animal plasmas were identified us

181 r, the mechanisms underlying NP retention of plasma proteins in the submucosa remain unclear.

182 r, the mechanisms underlying NP retention of plasma proteins in their submucosa remain unclear.

183 ding to fibrin and fibrin-associated clotted plasma proteins in tumor vessels.

184 45.3% of 18F-PFH was found to associate with plasma proteins in vivo in normal rats.

185 We detected changes to 418 plasma proteins in vivo, and detected changes to 262 pro

186 lized platelets in the presence of exogenous plasma proteins, in comparison with suspension-grown cel

187 luenced by interaction of the particles with plasma proteins, including coagulation factor X (FX), wh

188 mass spectrometry (MS) targeted detection of plasma proteins, including post-translational modificati

189 he circulating thyroid hormones are bound to plasma proteins, including three major thyroid hormone-b

190 h intravascular substances as hemoglobin and plasma proteins increases.

191 on on AP53 cells, further showing that these plasma protein inhibitors are active on GAS cells.

192 stinal digestion, intestinal permeation, and plasma protein interaction of polyphenols from a single

193 vitro bioaccessibility, bioavailability and plasma protein interaction of polyphenols from Annurca a

194 High abundance plasma proteins interfere with detection of potential pr

195 arrier function that restricts flow of large plasma proteins into tissues while allowing small molecu

196 Fetuin-A is a liver-derived plasma protein involved in the regulation of calcified m

197 Albumin is the most abundant plasma protein involved in the transport of many compoun

198 glass-based microarray, able to measure >600 plasma proteins involved in cell-to-cell communication,

199 dema or formation of a pseudocyst containing plasma proteins is a prominent characteristic of nasal p

200 igation of chiral interactions of drugs with plasma proteins is of fundamental importance for drug ef

201 C-reactive protein (CRP), an acute-phase plasma protein, is a major component of inflammatory rea

202 Serum AA protein (SAA), an acute phase plasma protein, is deposited extracellularly as insolubl

203 However, VA1 induced less plasma protein leakage and myeloid inflammatory cell rec

204 Microvascular plasma protein leakage is an essential component of the

205 cle or dorsal skin, but neutrophil-dependent plasma protein leakage was abolished.

206 loci explained up to 66% of interindividual plasma protein-level variation and, on average, accounte

207 with cell-type-specific gene expression and plasma protein levels sheds light on potential disease m

208 ithin a gene were analyzed for corresponding plasma protein levels using genome-wide association stud

209 Plasma protein levels were measured via enzyme-linked im

210 as performed, to evaluate the association of plasma protein levels with dopaminergic system integrity

211 ciation between ARDS-associated genotype and plasma protein levels.

212 ript by >70% and significantly reduced PCSK9 plasma protein levels.

213 ation defined by tumour mutational status or plasma protein levels.

214 ecovery of body weight, reduced glycosylated plasma proteins levels, and long-term survival without s

215 dema or formation of pseudocysts filled with plasma proteins, mainly albumin.

216 fic for C5a, suggesting that this ubiquitous plasma protein may have a more significant role in neutr

217 ween platelet glycoprotein (Gp) IIb/IIIa and plasma proteins mediate platelet cross-linking in arteri

218 ed studies of 3 include its binding to human plasma proteins, metabolic stability using human liver m

219 Plasma proteins (n = 163) were profiled in 44 patients w

220 Recently, a novel plasma protein named MBL/ficolin-associated protein-1 (M

221 Protein S (PS) is a multifunctional plasma protein of the hemostatic and inflammatory pathwa

222 io (a test showing relative amounts of major plasma proteins) of 0.92 (reference range, 0.8-2.0), a u

223 in a mean 70% reduction in circulating PCSK9 plasma protein (p<0.0001) and a mean 40% reduction in LD

224 ysiologic conditions, significant amounts of plasma protein pass the renal filter and are reabsorbed

225 the present study, we report that the inert plasma protein plasminogen (plg) acts as a key regulator

226 Pathogenic microbes acquire the human plasma protein plasminogen to their surface.

227 ain of Epf (EpfN) and increased by the human plasma protein plasminogen.

228 lbumin, but facilitates the loss of IgG from plasma protein pools.

229 ) hydrogel particles for removal of abundant plasma proteins, prior to proteome analysis by MS.

230 tion of genetic variants affecting the human plasma protein profile by combining high-throughput and

231 l-to-cell communication, was used to measure plasma protein profiles in 96 HIV-infected, treatment-na

232 isease (CHD-PAH) has serious consequence and plasma protein profiles in CHD-PAH are unknown.

233 These data suggest that plasma protein profiles might improve the prediction of

234 However, although changes of plasma protein profiles reflect physiological or patholo

235 We compared plasma protein profiles with ex vivo islet secretome and

236 In the present study, plasma protein profiling was compared among NEC, sepsis

237 -feet from cerebral microvessels, leakage of plasma proteins, reduction in expression of endothelial

238 However, the foetal blood-brain barrier to plasma proteins remained intact.

239 owever, the exact physiological role of this plasma protein remains enigmatic.

240 Western ligand blot analyses of vitreous and plasma proteins separated by two-dimensional gel electro

241 The plasma protein Serum Amyloid P (SAP) inhibits fibrocyte

242 The plasma protein serum amyloid P (SAP) reduces neutrophil

243 differentiation is strongly inhibited by the plasma protein serum amyloid P (SAP), and healthy tissue

244 dosis always contain the nonfibrillar normal plasma protein, serum amyloid P component (SAP).

245 Our results suggest that plasma proteins should be evaluated as a tool for progno

246 aminase-specific labeling to identify FXIIIa plasma protein substrates and their reactive residues.

247 h as scavenger receptors on macrophages, and plasma proteins, such as C-reactive protein (CRP).

248 d protein-1 (MAP-1) is a recently discovered plasma protein that acts as an upstream inhibitor of the

249 ding protein (C4BP), a complement regulatory plasma protein that attenuates the classical and lectin

250 Haptoglobin is a plasma protein that binds free hemoglobin, thereby inhib

251 Kallistatin is a plasma protein that exhibits pleiotropic effects in vaso

252 Serum amyloid A (SAA) is an acute-phase plasma protein that functions in innate immunity and lip

253 Adiponectin is a fat-derived plasma protein that has cardioprotective roles in obesit

254 von Willebrand factor (VWF) is a multimeric plasma protein that mediates platelet adhesion to sites

255 on of iron from transferrin, the circulating plasma protein that normally delivers iron to cells by r

256 Complement factor H (fH) is a plasma protein that regulates activation of the alternat

257 a receptor for vitronectin (Vn), an abundant plasma protein that regulates the terminal pathway of th

258 ase-3 (GPx-3) is a selenocysteine-containing plasma protein that scavenges reactive oxygen species in

259 In univariable analyses, the only plasma protein that was associated with overall survival

260 We also present an 'adsorbome' of 125 plasma proteins that are known to associate with nanomat

261 means of identifying preclinical changes in plasma proteins that are potentially relevant to the ear

262 m of this study was to identify and validate plasma proteins that are predictive of outcome in IPF.

263 ue to the blocking of radioligand binding to plasma proteins that elevated the free fractions of the

264 includes a predominant contribution of blood plasma proteins that is conserved with human SF.

265 cquisition, assimilation and/or recycling of plasma proteins that predicted overwinter survival.

266 Further, we identified 98 plasma proteins that still foul current "protein-resista

267 was a significant increase in the number of plasma proteins that were related to endocrine system di

268 0183) site-specific changes in the number of plasma proteins that were related to tumor formation, re

269 profiling of a larger portion of circulating plasma proteins (the plasma proteome) will provide oppor

270 o bind, absorb, and load their granules with plasma proteins, this report is one of the first to expl

271 How fibronectin (FN) converts from a compact plasma protein to a fibrillar component of extracellular

272 a list of proteins or peptides against known plasma proteins to assess novelty of their data set.

273 ier changes that allow a different subset of plasma proteins to enter vitreous fluids.

274 oss-talk couples transendothelial leakage of plasma proteins to the cytokine circuitry that coordinat

275 ssed mature liver genes such as cytochromes, plasma proteins, transporters, and other hepatic enzymes

276 The plasma protein transthyretin (TTR) is linked to human am

277 studies, creating a reference dataset of 496 plasma protein turnover rates from 4 healthy adults.

278 This study is the first to measure global plasma protein turnover rates in rats in vivo, measure v

279 le is known about how concentrations of many plasma proteins vary between individuals from different

280 es the blood flow through its binding to the plasma protein von Willebrand factor (VWF) and transmits

281 The plasma protein von Willebrand factor (VWF) is essential

282 Plasma protein von Willebrand factor (VWF) mediates adhe

283 A core signature of 46 plasma proteins was commonly modulated in all three infe

284 Normal sialylation of plasma proteins was observed in spite of NANS deficiency

285 ween groups, and biochemical profiling of 40 plasma proteins was performed to identify proteins that

286 the MudPIT-SRM approach to profile abundant plasma proteins, we demonstrated mean increases in peak

287 ng the corresponding effects on inflammatory plasma proteins, we identified cathepsin S as a lead ind

288 It showed low binding to human plasma proteins, weakly inhibited cytochrome P450 isofor

289 more inflammatory than those to which other plasma proteins were adsorbed.

290 Differential plasma proteins were first detected by iTRAQ proteomic t

291 tabolic enzymes, some myofibrillar and blood plasma proteins were identified, which were characterise

292 Concentrations of 54 high-abundance plasma proteins were measured simultaneously by liquid c

293 Plasma proteins were sampled from male and female fish f

294 shing the binding affinity between drugs and plasma proteins, which is a critical factor to develop e

295 ted to improve the fraction unbound to human plasma protein while retaining biochemical potency.

296 Human alpha-1-antitrypsin (A1PI) is a plasma protein with the function of protecting lung tiss

297 Hx is the plasma protein with the highest binding affinity to heme

298 , and turnover rates were quantified for 157 plasma proteins with half-lives ranging 0.3-103 days.

299 poproteins, 135 lipid species, and 211 other plasma proteins with incident CVD (91 events), defined a

300 The interaction of plasma proteins with metal oxide nanoparticles (NPs) is